The goal of the multicenter drug surveillance project AMSP (”Arzneimittelsicherheit
in der Psychiatrie”) is the monitoring, assessment and analysis of adverse drug reactions
(ADR) of psychopharmalogical drugs. We report about a 23 year-old patient with a depressive
episode. He developed severe pseudohallucinations under a treatment with moclobemide.
The symptoms occur 6 days after starting the medication and decline within two days
after stopping moclobemide. The term "pseudohallucinations" is discussed controversially
but still of high interest.
References
- 1
Adityanjee B.
Clinical significance of pseudohallucinations.
Gen Hosp Psychiatry.
2000;
2
124-126
- 2
Bourgeois J A, Thomas D, Johansen T. et al .
Visual hallucinations associated with fluoxetine and sertraline.
J Clin Psychopharmacol.
1998;
18
482-483
- 3
Degner D, Grohmann R, Kropp S. et al .
Severe drug reactions of antidepressants: results of the German multicenter drug surveillance
program AMSP.
Pharmacopsychiatry.
2004;
37/S 1
39-45
- 4
Hoffmann W.
A case of tranylcypromine-induced hallucination.
Psychiatr Prax.
1993;
20
116
- 5
Isbister G K, Hackett L P, Dawson A H. et al .
Moclobemide poisoning: toxicogenetics and occurrence of serotonin toxicity.
Br J Clin Pharmacol.
2003;
4
441-450
- 6
Laux G, Baier D.
Qualtiy-monitoring of psychotropic drug therapy in post-marketing surveillance. Results
of a drug utilization observation (DUO) study on moclobemide.
Pharmacopsychiatry.
1997;
30
21-27
- 7
Takeshi T.
Tricyclic-induced musical hallucinations and states of relative sensory deprivation.
Biol Psychiatry.
1995;
38
192-193
- 8
van der Zwaard R, Polak M A.
Pseudohallucinations: A pseudoconcept? A review of the validity of the concept related
to associate symptomatology.
Compr Psychiatry.
2001;
42
42-50
Dr. Detlef Degner
Department of Psychiatry and Psychotherapy
Georg-August University Göttingen
Von-Siebold Str. 5
37073 Göttingen
Germany
Telefon: +49 551 39 6612
Fax: +49 551 39 6668
eMail: ddegner@gwdg.de